Mammalian target of rapamycin complex 1 (mTORC1) Is required for mouse spermatogonial differentiation in vivo

Jonathan T. Busada a, Bryan A. Niedenberger a, Ellen K. Velte a, Brett D. Keiper b, Christopher B. Geyer a,c,*

a Department of Anatomy and Cell Biology, East Carolina University, Greenville, NC, USA
b Department of Biochemistry and Molecular Biology, East Carolina University, Greenville, NC, USA
c East Carolina Diabetes and Obesity Institute, East Carolina University, Greenville, NC, USA

Article history:
Received 28 April 2015
Received in revised form 2 August 2015
Accepted 3 August 2015
Available online 5 August 2015

Keywords:
Spermatogonia
Retinoic acid
Testis
Spermatogenesis
mTOR

A B S T R A C T

Spermatogonial stem cells (SSCs) must balance self-renewal with production of transit-amplifying progenitors that differentiate in response to retinoic acid (RA) before entering meiosis. This self-renewal versus differentiation spermatogonial fate decision is critical for maintaining tissue homeostasis, as imbalances cause spermatogenesis defects that can lead to human testicular cancer or infertility. A great deal of effort has been exerted to understand how the SSC population is maintained. In contrast, little is known about the essential program of differentiation initiated by retinoic acid (RA) that precedes meiosis, and the pathways and proteins involved are poorly defined. We recently reported a novel role for RA in stimulating the PI3/AKT/mTOR kinase signaling pathway to activate translation of repressed mRNAs such as Kit. Here, we examined the requirement for mTOR complex 1 (mTORC1) in mediating the RA signal to direct spermatogonial differentiation in the neonatal testis. We found that in vivo inhibition of mTORC1 by rapamycin blocked spermatogonial differentiation, which led to an accumulation of undifferentiated spermatogonia. In addition, rapamycin also blocked the RA-induced translational activation of mRNAs encoding Kit, SOHLH1, and SOHLH2 without affecting expression of STRA8. These findings highlight dual roles for RA in germ cell development – transcriptional activation of genes, and kinase signaling to stimulate translation of repressed messages required for spermatogonial differentiation.

© 2015 Elsevier Inc. All rights reserved.

1. Introduction

Retinoic acid (RA) is required for inducing both spermatogonial differentiation and subsequent entry into meiosis (Bowles et al., 2006; Koubova et al., 2006). After birth in the mouse, subsets of spermatogonia begin to differentiate in response to RA at ~P3-4, as indicated by their expression of STRA8 and Kit (Busada et al., 2014; Niedenberger et al., 2015; Snyder et al., 2010; Zhou et al., 2008). However, germ cells do not enter meiosis in response to RA until ~P10 (Hogarth and Griswold, 2013). This reveals that the processes of differentiation and meiotic entry are temporally separated by ~7 days in the neonate (which lengthens to 8.6 days in the adult). It has been proposed that the reduced time in the neonate may be because some of the steps are skipped or because cell proliferation is accelerated by the increased temperature at which spermatogenesis proceeds in the neonate (37°C in neonates versus 33°C in adults) (Kluin et al., 1982). During this approximately week-long differentiation period, type A1 spermatogonia successively become type A2, A3, A4, In, and B before entering meiosis as preleptotene spermatocytes (de Rooij, 2001; de Rooij and Griswold, 2000; Kluin et al., 1984). Spermatogonia apparently cannot be induced to precociously enter meiosis in response to exogenous RA (Busada et al., 2014; Niedenberger et al., 2015; Endo et al., 2015), which implies that these sequential spermatogonial divisions are required. However, little is known about the cellular processes that must occur or the molecular pathways that regulate them in differentiating spermatogonia prior to meiotic initiation. A primary reason for this lack of knowledge is that there are few changes in steady-state mRNA levels during differentiation (Chan et al., 2014; Shima et al., 2004; Zhou et al., 2008). Without dramatic changes in the transcriptome, scientists have lacked identified targets (pathways, proteins) for focused studies.

A number of recent genome-wide studies have revealed that the transcriptome imperfectly predicts the proteome (estimates range from ~40% to 80% agreement) (Li et al., 2014; Schwahnhauser et al., 2011; Vogel and Marcotte, 2012), and there is likely to be considerable variation in this level of disconnect in different
cell types and under different conditions. Our previous studies suggest that a majority of gene expression changes required for spermatogonial differentiation occur at the posttranscriptional level (Busada et al., 2015; Chappell et al., 2013). We previously showed that RA treatment leads to increased phosphorylation of the master regulatory kinase mammalian target of rapamycin (mTOR) (Busada et al., 2015), indicating it is activated in differentiating spermatogonia. This is accompanied by enhanced translation of repressed Kit mRNAs through activation of the PI3K/PDK1 (also termed PDK1)/AKT signaling network (Busada et al., 2015; Hermann et al., 2015). MTOR exists in functionally distinct protein complexes (mTORC1 and mTORC2), which integrate numerous cues to regulate, in broad terms, cellular growth and differentiation (mTORC1) or the actin cytoskeleton and insulin signaling (mTORC2) (reviewed by (Fingar and Blenis, 2004; Hay and Hall, 2014)). This has been suggested to be due in part to differential effects on downstream substrates such as EIF4EBP1 and/or RPS6KB1/2 (Choo et al., 2008). Rapamycin can be administered in vivo, and actually extends the lifespan of lower organisms (Dinkova et al., 2005; Henderson et al., 2009; Kimble and Crittenden, 2007; Mendez and Richter, 2001; Song et al., 2010). Activated RPS6KB1/2 phosphorylates the 40S ribosomal subunit RPS6, leading to activation of ribosomes and enhanced mRNA translation. This activity is essential for the translational control of the TOP mRNAs, which have S′ oligopyrimidine tracts, are activated by changes in cellular metabolism, and often encode components of the translational machinery (Hamilton et al., 2006; Meyuhas and Kahan, 2014).

The mTOR complexes differ in their sensitivity to rapamycin, a macrolide antifungal compound originally isolated from the soil bacterium Streptomyces hygroscopicus that has an expanding number of clinical uses. Rapamycin acutely inhibits mTORC1 activity, but has also been shown to inhibit mTORC2 in some contexts following prolonged exposure (Laplante and Sabatini, 2012; Brown et al., 1994; Sabatini et al., 1994). The effects of rapamycin vary significantly depending on the cell type involved. Some cell types appear to be quite rapamycin-insensitive, while others slow or cease proliferating, fail to differentiate, and/or undergo apoptosis (Laplante and Sabatini, 2012; Li et al., 2014; Shimobayashi and Hall, 2014). This has been suggested to be due in part to differential effects on downstream substrates such as EIF4EBP1 and/or RPS6KB1/2 (Choo et al., 2008). Rapamycin can be administered in vivo, and actually extends the lifespan of lower organisms and mice (Harrison et al., 2009; Anisimov et al., 2011), reviewed in Li et al., 2014). In addition, studies have suggested a link between mTORC1 and spermatogonial cell fate regulation both in vitro and in vivo (Busada et al., 2015; Chappell et al., 2013; Feng et al., 2000; Hobbs et al., 2015; Hobbs et al., 2010; Kofman et al., 2013).

Studying the effects of mTORC1 inhibition by rapamycin has direct relevance for human male reproductive health. Rapamycin analogs (Sirolimus and Everolimus) are currently used to reduce cellular proliferation as part of immunosuppressive and chemotherapeutic regimens given to organ transplant, cardiology, and cancer patients (Laplante and Sabatini, 2012; Li et al., 2014; Ashworth and Wu, 2014; de Pablo et al., 2013; Eyre et al., 2014; Ganschow et al., 2014; Ng et al., 2014; Peddi et al., 2013). These drugs can cause reversible human male infertility with unclear etiology (Boobes et al., 2010; Framarino-dei-Malatesta et al., 2013; Huyghe et al., 2007; Zaza et al., 2013; Zuber et al., 2008). Specifically, rapamycin analog treatments caused a block in spermatogonial differentiation in a human patient (Deutsch et al., 2007) as well as in a study using rats, although no detailed analyses were performed (Chen et al., 2013). Both treated humans and rats exhibit reduced testosterone (T) levels due to inhibition of the hypothalamic–pituitary–gonadal axis. However, this may not cause a defect in spermatogonial differentiation, but rather in progression through meiosis, at least in rodents (Walker, 2011). Infertility is a significant quality of life concern for reproductive-aged male organ transplant and cancer patients, and to-date no comprehensive studies have explored the mechanism of action of mTOR inhibition during spermatogenesis.

Here, we examine the effects of rapamycin-mediated mTORC1 inactivation on spermatogonial differentiation in vivo in the mouse. Our results reveal that mTORC1 activation is dispensable for the maintenance of undifferentiated spermatogonia, but that it is required for spermatogonial proliferation and differentiation prior to meiotic initiation. In addition, we find that rapamycin inhibition of mTORC1 blocks the RA-induced translation of repressed mRNAs encoding KIT, SOHLH1, and SOHLH2, which are essential regulators of spermatogonial differentiation. However, rapamycin treatment did not block the expression of STRA8, a direct transcriptional target of RA. This reveals that spermatogonia exhibit dual responses to RA in the form of transcriptional activation and kinase signaling-enhanced translation of repressed mRNAs. In addition, these results provide critical insight into the male infertility that can result as an adverse side effect of the clinical use of rapamycin analogs.

2. Results
2.1. Rapamycin treatment reduces testicular size and arrests germ cell development

Our previous study revealed that RA activated the PI3K/AKT kinase signaling network in differentiating spermatogonia (Busada et al., 2015). This also resulted in phosphorylation (implying activation) of mTOR, which acts in mTORC1 to direct cellular growth, proliferation, and differentiation (reviewed in Laplante and Sabatini, 2012). Here, we addressed the requirement for mTORC1 in spermatogonial differentiation in vivo by feeding vehicle alone or rapamycin to neonatal mice once daily beginning at P1, which is 2–3 days prior to the onset of normal differentiation. Mice were then euthanized at P4 and P8 (Fig. 1A), and testes were harvested for various analyses. Although animals appeared healthy, there was a significant decrease in body weight and testis size and weight in response to rapamycin treatment at both P4 and at P8 (Fig. 1C and D). Testis weights were normalized to total body weight and there were 26% and 31% decreases at P4 and P8, respectively (Fig. 1E). Since reduced testis weight often results from reduced cellularularity, we examined Bouin’s-fixed testis sections stained with H&E from vehicle- and rapamycin-treated mice. Germ cell types in the neonatal testis are readily distinguished based on their characteristic size, location, and nuclear morphology (Kluin et al., 1984; Drumond et al., 2011; Kluin and de Rooij, 1981). Vehicle-treated control testes from P4 and P8 mice had the germ cells at the expected stages of development (Fig. 1G and I) (de Rooij, 2001; Drumond et al., 2011; de Rooij, 1998; De Rooij and Lok, 1987). At P8, there were abundant spermatogonia and preleptotene spermatocytes and a small number of meiotic leptotene spermatocytes. In contrast, rapamycin-treated P8 testes had significantly reduced testis cord diameters (Fig. 1F) and many fewer germ cells, with the most advanced stage resembling undifferentiated spermatogonia (Fig. 1H and I).
2.2. Rapamycin inhibits mTORC1 activity in spermatogonia

Before carefully examining the phenotype of rapamycin-treated testes, we verified that rapamycin treatment inhibited mTORC1 activity as expected. We examined the phosphorylation of mTOR as well as RPS6, which is an indirect target downstream of activated mTORC1. There was a near-complete loss of p-mTOR and p-RPS6 in response to rapamycin (Fig. 2A–D). We recently reported that RA caused a dramatic nuclear-to-cytoplasmic relocalization of FOXO1 (Busada et al., 2015), which is indicative of AKT activation (Brunet et al., 1999; Goertz et al., 2011). Since this signaling step is generally upstream of mTOR phosphorylation, we hypothesized that rapamycin inhibition would not alter FOXO1 localization. Indeed, there was no appreciable difference in the ratios of cytoplasmic: nuclear FOXO1 in vehicle- or rapamycin-treated germ cells (Fig. 2E and F). Therefore, we conclude that rapamycin treatment inhibited mTORC1 activation in spermatogonia without affecting upstream activation of signaling components such as AKT, which implies that mTORC2 signaling was not perturbed.

2.3. Undifferentiated spermatogonia accumulate in rapamycin-treated testes

Rapamycin treatment from P1 to P4 and P1 to P8 resulted in an apparent reduction in germ cells (Fig. 1H and J). We quantified this in vehicle- and rapamycin-treated mice by immunostaining for DDX4, a pan germ cell marker in the neonatal testis. There were reduced numbers of DDX4+ germ cells at P4 (−1.63 ± 0.03-fold) and P8 (−2.74 ± 0.04-fold) (Fig. 3A–D, M and N). The decreased number of germ cells could result from a rapamycin-induced
increase in apoptosis, although we did not see evidence for this in H&E-stained sections (Fig. 1G–J, data not shown). We nonetheless assessed this possibility by immunostaining for cleaved PARP1, an accepted marker for apoptotic cells. As expected, there was no significant increase in cleaved-PARP1+ cells in rapamycin-treated testes at P4 or P8 (P1-4 vehicle-treated = 0.17 ± 0.06 cleaved-PARP1+ cells/testis cord, P1-4 rapamycin-treated = 0.13 ± 0.06 cleaved-PARP1+ cells/testis cord, Fig. 3E–H), indicating that apoptosis was not responsible for the reduced germ cell numbers. We next assessed whether there was a reduction in germ cell proliferation in response to rapamycin. We first immunostained using an antibody against MKI67, which marks actively proliferating cells in all stages of the cell cycle except in G0 (Gerdes et al., 1983; Lopez et al., 1991). There was no difference in MKI67 staining at P4 in response to rapamycin treatment. However, there were significantly fewer MKI67+/DDX4+ cells at P8 in rapamycin treated testes. (1.85 ± 0.37-fold, Fig. S1A–E). We next injected vehicle- and rapamycin-treated mice with BrdU 10 h prior to euthanasia on P4 and P8. There were 1.9-fold fewer BrdU+ germ cells in response to rapamycin at P4 and P8 (Fig. S1–L, O and P). We also assessed effects of rapamycin on Sertoli cell numbers by immunostaining for the Sertoli cell marker GATA4, and found that...
there was no appreciable change at P4 (P1-4 vehicle = 18.3 ± 0.6 GATA4+ cells/testis cord, P1-4 rap-treated = 19.67 ± 7.3 GATA4+ cells/testis cord) or P8 (P1-8 vehicle = 18.8 ± 4.0 GATA4+ cells/testis cord, P1-8 rap-treated = 17.1 ± 15.5 GATA4+ cells/testis cord, Fig. S2). Therefore, we conclude that rapamycin inhibited germ cell proliferation without increasing apoptosis or changing Sertoli cell numbers.

We next tested whether mTORC1 inhibition by rapamycin prevented the normal differentiation of spermatogonia. Based on the apparent accumulation of undifferentiated spermatogonia at P4 and P8 in response to rapamycin (Fig. 1G–J), it appeared that spermatogonial differentiation was blocked by rapamycin treatment. We assessed whether spermatogonia upregulated markers of differentiation (KIT, SOHLH1, and SOHLH2) in the absence of
mTORC1 function. Each marker was readily detectable in spermatogonia in vehicle-treated testes at P4 (Fig. 4A, C, and E). In contrast, KIT, SOHLH1, and SOHLH2 were barely detectable in a few spermatogonia in rapamycin-treated testes (Fig. 4B, D, and F). The absence of differentiation markers suggests that the germ cells remained in an undifferentiated state in the absence of mTORC1 activity. We tested this by immunostaining for GFRA1, an established marker of undifferentiated spermatogonia, which together with RET forms the receptor for GDNF (Kubota et al., 2004; Meng et al., 2000). We found that at P8 66% of DDX4þ spermatogonia were GFRA1þ in response to rapamycin, which represented a 5.1-fold increase over vehicle-treated controls (Fig. 5A–C). We further explored this using a recently created transgenic mouse line, in which the spermatogonial stem cell (SSC) population is marked by the expression of eGFP under the control of the Id4 promoter (Chan et al., 2014). Recent work has demonstrated that SSC activity resides within the Id4-GFPþ cell population (Chan et al., 2014). To test if treatment with rapamycin affects formation or size of the SSC population, we treated Id4-GFP pups with vehicle or rapamycin from P1 through P7 and euthanized them on P8. The results demonstrated that 19% of the total germ cell population was GFP-bright in both the vehicle- and rapamycin-treated testes (Fig. 5D–

Fig. 4. mTOR activation is required for induction of SOHLH1, SOHLH2, and KIT protein. Immunostaining of mice treated with vehicle (A, C, and E) or rapamycin (B, D, and F) and euthanized at P4. Sections were stained with anti-SOHLH1 (A and B), anti-SOHLH2 (C and D), or anti-KIT (E and F). Phalloidin (red) was added to visualize testis cords. Scale bar = 50 μM.
indicating that the size of the SSC pool was not affected by mTORC1 inhibition.

2.4. Rapamycin blocks RA-enhanced translation of repressed mRNAs

Finally, we investigated how KIT, SOHLH1, and SOHLH2 protein levels were dramatically reduced following inhibition of mTORC1. We previously found that mRNAs for Kit, Sohlh1, and Sohlh2 became associated with heavy polysomes at P4 (Chappell et al., 2013), which coincided with the appearance of detectable protein. In a separate study, we reported that RA activated translation of repressed Kit mRNAs during differentiation by inducing heavy polysome occupancy without a dramatic increase in their abundance (Busada et al., 2015). We therefore examined whether Sohlh1 and Sohlh2 mRNAs were regulated similarly in response to RA. In response to RA, both SOHLH1 and SOHLH2 protein levels increased dramatically (Fig. 6A–D), and as previously shown, RA treatment also induced Kit translation (Fig. S3 A and B, (Busada et al., 2014, 2015)). This increase in protein was not accompanied by an increase in steady-state mRNA levels (Fig. 6E and F). We then performed polysome gradient analysis to test whether RA induced Sohlh1 and Sohlh2 mRNA heavy polysome occupancy for efficient translation, as we recently showed for Kit (Busada et al., 2015). Polysome gradients allow for the fractionation of mRNAs based on their association with ribonucleoprotein particles (RNPs), ribosome subunits, and light and heavy polysomes. The identification of specific mRNAs within sedimenting fractions reflects their translational efficiency, with those in heavy polysomes being most efficiently translated (reviewed in (Masek et al., 2011)). We pooled heavy polysome fractions in testes from vehicle- and RA-treated mice and discovered that Sohlh1, Sohlh2, and Kit mRNAs became enriched in heavy polysomes in response to RA (Fig. 6E and F and Fig. S3C). We conclude that, like Kit, Sohlh1 and Sohlh2 mRNAs are not efficiently translated in undifferentiated spermatogonia, and become activated at the level of translation in response to RA.

We next examined whether rapamycin treatment would inhibit this RA-induced translational activation. We utilized P4 rapamycin-treated testis, as they contained more similar numbers of germ cells to vehicle-treated controls than at P8 (Fig. 3A–D). In response to rapamycin, there was a small but statistically significant decrease in steady-state mRNA levels for Sohlh1, Sohlh2, and Kit (Fig. 7A), which corresponded closely with the decrease in the germ cell population at P4 (Fig. 3A and B). We found that rapamycin treatment caused a significant decrease in polysome occupancy for each of these mRNAs in comparison with vehicle-treated controls (Fig. 6A).

Lastly, because rapamycin treatment could affect other cells in the testis and reduce endogenous RA levels, we tested whether exogenous RA could induce STRA8 a known transcriptional target required for meiotic initiation (Busada et al., 2014; Zhou et al., 2008; Anderson et al., 2008; Griswold et al., 2012; Mark et al., 2008), in testes of rapamycin-treated mice. We assessed this using testes from mice euthanized at P4 following treatment with vehicle or rapamycin from P1-4 and injected with RA at P3 (Fig. 7B).
We found that RA induced STRA8 and KIT in vehicle-treated control testes, as expected (Fig. 7C). In rapamycin-treated testes, KIT was not induced, as shown above (Fig. 4F and Fig. 7D). However, STRA8 was induced in response to RA. As expected, exogenous RA treatment induced \( \text{Stra8} \) mRNA in rapamycin-treated testes (Fig. S3D). This indicates that RA activates expression of STRA8 and KIT in spermatogonia through distinct mechanisms (mTORC1-independent for STRA8, mTORC1-dependent for KIT). Taken together, results from the current study indicate that mTORC1 activation is a critical step downstream of RA in the translational activation of essential regulators of spermatogonial differentiation such as KIT, SOHLH1, and SOHLH2.

3. Discussion

3.1. Summary

Here, we show that inhibition of mTORC1 activity in the testis by rapamycin has profound effects on spermatogonial development. Rapamycin inhibited spermatogonial proliferation and differentiation, which reduced the germ cell population overall, but increased the percentage of undifferentiated spermatogonia (GFRA1\(^+\)) and did not affect the SSC pool (Id4-GFP bright cells). At the molecular level, we found that rapamycin changed the spermatogonial response to RA. While \( \text{Stra8} \) mRNA and protein were still induced in rapamycin-treated testes in response to RA, the enhanced translation of \( \text{Sohlh1} \), \( \text{Sohlh2} \), and \( \text{Kit} \) mRNAs was blocked. This supports the concept that RA exerts dual roles in the activation of transcription and translation in spermatogonia, and that blocking mTORC1 activation can functionally decouple these actions. Altogether, our results reveal an essential role for mTORC1 activation in RA induced enhanced translation of genes required for spermatogonia proliferation and differentiation, and provide insight into the male infertility phenotype observed following administration of rapamycin to both rodents and humans.

3.2. The diverse effects of rapamycin in various cell types

Rapamycin has wide-ranging cell- and tissue-specific effects. In animal models, rapamycin can exert a variety of positive consequences including lifespan extension, reduction of cancer progression, improved organ transplant retention, neuroprotection from damage caused by diseases such as Alzheimer’s, Huntington’s, and Parkinson’s, and suppression of high fat diet-induced obesity (reviewed in Li et al., 2014). These diverse outcomes highlight the observations from many laboratories that the molecular signaling through mTORC1 varies in a cell-dependent context. In particular, mTORC1 inhibition can alternatively lead to reduced proliferation, increased apoptosis, and blocked cellular differentiation (reviewed in Laplante and Sabatini, 2012). In this study, treatment with rapamycin prior to the onset of differentiation (at P3-4) did not result in germ cell loss by apoptosis, but rather a near-complete inhibition of differentiation such that no cells were seen preparing to enter meiosis as preleptotene spermatocytes at P8. Our results also indicate that Sertoli cell numbers were unaffected by the treatment, and there were no significant changes in their position or appearance. The prolonged exposure to rapamycin can also inhibit the function of mTORC2, although this varies widely with cell type (Sarbassov et al., 2006). This is not likely occurring in this study; since activated mTORC2 phosphorylates and activates AKT (Hay, 2011), we would expect that its inhibition would lead to an increase in cytoplasmic FOXO1, which we did not observe.
3.3. The role of RA in mTORC1 activation and enhanced translation in vivo

During differentiation, spermatogonia respond to RA by proliferating and undergoing largely unknown cellular changes that precede meiosis. A primary reason for this lack of knowledge about spermatogonial differentiation is that there are very few changes in steady-state mRNA levels between undifferentiated and differentiating spermatogonia (Chan et al., 2014; Shima et al., 2004; Zhou et al., 2008). Without dramatic changes in the transcriptome, scientists have lacked targets (pathways, proteins) for focused studies. The classic mechanism by which RA controls gene expression is through modulating transcription of RA-responsive genes such as \textit{Stra8} and \textit{Rec8}, which are required for entry into and progression through meiosis (Anderson et al., 2008; Mark et al., 2008; Koubova et al., 2014; Xu et al., 2005). Here and in a previous report (Busada et al., 2015), we identify a novel mechanism by which RA signals through the PI3K/AKT/mTOR signaling pathway to initiate the efficient translation of mRNAs required for spermatogonia differentiation. This reveals that RA can regulate gene expression by multiple mechanisms. In addition to \textit{Kit}, we report here that the mRNAs for \textit{Sohlh1} and \textit{Sohlh2}, which also encode essential determinants of spermatogonial differentiation, are stimulated by RA to become recruited into polysomes, resulting in a dramatic increase in protein levels without significant increases in steady-state mRNA abundance. This discrepancy between abundant mRNA and undetectable or barely detectable protein was previously alluded to in studies from the Rajkovic laboratory (D. Ballow et al., 2006; D.J. Ballow et al., 2006). Additional evidence for the transcription of these genes in undifferentiated spermatogonia comes from whole tubule explant cultures, in which GDNF increased mRNA levels for both \textit{Kit} and \textit{Sohlh1}, but did not induce protein expression (Grasso et al., 2012). Therefore, it is possible that a subset of genes is transcribed in undifferentiated spermatogonia, and that these mRNAs are poorly translated until RA activates the PI3K/AKT pathway to direct their mobilization into heavy polysomes for efficient translation. Our data supports a model whereby mTORC1 activation by RA leads to the translational activation of specific mRNAs required for spermatogonial differentiation (Fig. 8). There is precedent for a similar posttranscriptional regulation downstream of RA in local translation at neuronal dendritic and axonal termini. In that paradigm, RA binds RARA to activate the PI3K/AKT signaling pathway and stimulate translation of repressed mRNAs including \textit{Gria1}/\textit{Glur1} (Aoto et al., 2008; Chen and Napoli, 2008; Chen et al., 2008; Maghsoodi et al., 2008; Masia et al., 2007). Furthermore, a study found using the F9 cell line that RARG associated with the p-85 regulatory subunit of PI3K, and that PI3K–AKT activation by RA was required for F9 cell differentiation (Masia et al., 2007; Lopez-Carballe et al., 2002).

It is clear that certain mRNAs are exceedingly sensitive to translational suppression by rapamycin (Thoreen et al., 2012). These disproportionately affected mRNAs may have a stronger reliance on cap-dependent translation. Previous studies have shown that mTORC1-sensitive mRNAs generally contain complex 5’ UTRs that are positively regulated by phosphorylation of eIF-4EBP1 (Hay and Sonenberg, 2004) or are members of the class of 5’ TOP mRNAs which contain a 5’ terminal oligopyrimidine tract (Meyuhas, 2000). It is clear that \textit{Kit}, \textit{Sohlh1}, and \textit{Sohlh2} mRNAs appear to be sensitive to translational repression during...
spermatogenesis in vivo. This effect is mimicked by mTORC1 inhibition. Future studies will be aimed at identifying features within the UTRs that regulate translational repression and activation during spermatogenesis.

Germ cells are exposed to high levels of RA within discrete segments of the seminiferous cords (in the neonate and juvenile) and tubules (in the adult). In the adult, RA levels are highest along the seminiferous tubules at stages VII–VIII of the epithelial cycle (Hogarth et al., 2015). This provides an explanation for how RA can regulate three distinct events simultaneously in different cell types, as they all occur at these stages: differentiation of types Aα, Aβ, and Aγ into A1 spermatogonia, meiotic initiation of preleptotene spermatocytes, and spermiation of condensed spermatids. Indeed, RA has been shown to be required for each of these processes (reviewed in de Rooij, 2001; Griswold et al., 2012; Bowles and Koopman, 2007; O’Donnell et al., 2011).

One interesting point to consider is that, although RA is required for the initiation of spermatogonial differentiation (to A1 spermatogonia), the subsequent divisions (A2, A3, A4, In, B) occur in levels of low or absent RA (Hogarth et al., 2015). It is possible, then, that an important role of RA in spermatogonia is to stimulate the translation of mRNAs encoding KIT, which binds KITL to signal through the same PI3K/AKT/mTOR signaling pathway in spermatogonia in culture (Feng et al., 2000; Kissel et al., 2000). By doing so, RA may signal through PI3K/AKT initially, and then the newly synthesized KIT receptor would bind KITL and maintain mTORC1 activation during these later differentiation stages when levels of RA are low or absent. This scenario would explain how the mRNAs for Kit, Sohlh1, and Sohlh2 would remain efficiently translated despite low levels of RA.

3.4. mTORC1 activity in germ cells

Previous studies have suggested a role for mTORC1 in spermatogonial fate determination. In the first study, rapamycin blocked proliferation (incorporation of BrdU) in cultured spermatogonia and prevented KITL-induced phosphorylation of RPS6KB1, suggesting that PI3K/AKT signaling was required in vivo (Feng et al., 2000). In the second study using spermatogonia isolated from juvenile mice, it was concluded that ZBTB16/PLZF repressed mTORC1 activity by maintaining modestly higher steady-state mRNA levels (~3-fold) of an indirect negative regulator, REDD1 (Hobbs et al., 2010). However, it was recently reported that REDD1 KO mice are viable and fertile, with no apparent defects in spermatogenesis (Notini et al., 2012). In addition, proliferating/differentiating mTORC1-active neonatal spermatogonia contain abundant ZBTB16 (Niedenberger et al., 2015), suggesting this model does not fully explain mTORC1 regulation in differentiating spermatogonia in vivo. In a third study, rapamycin was administered to adult testis tubules maintained in hanging drop cultures for 24 h (Sahin et al., 2014). As expected, this reduced levels of p-mTOR, p-RPS6KB1, and p-EIF4EBP1 in spermatogonia and preleptotene spermatocytes. In addition, steady-state levels of PCNA and STRA8 were reduced, although these were assessed by western blot analysis of whole tubule lysates (Sahin et al., 2014). Since STRA8 levels are highest in preleptotene spermatocytes within stage VIII tubules (Zhou et al., 2008; Endo et al., 2015; Hogarth et al., 2015), it is unclear whether the reduction in STRA8 protein levels following short-term rapamycin treatment was from impaired expression in spermatogonia (implying impaired differentiation) or in preleptotene spermatocytes. In a fourth study, Hobbs and colleagues generated germ cell KO mice for Tsc2, which encodes an indirect repressor of mTORC1 activation. Therefore, Tsc2 KO germ cells would be predicted to have elevated mTORC1 activity. When Tsc2 was deleted beginning in fetal prospermatogonia (by Ddx4-Cre), there were fewer undifferentiated spermatogonia (ZBTB16+), and an increased number of atrophic tubules in the adult. However, this incomplete effect suggests that loss of TSC2 either did not increase mTORC1 activation in all undifferentiated spermatogonia, or that a subset of spermatogonia differ in their response to mTORC1 activation. Here, we did not see a change in the Idd4-GFP+ SSC-containing population in response to rapamycin treatment, which indicates that mTORC1 activity is low or not required in SSCs. Hobbs et al. found that Tsc2 deletion in differentiating spermatogonia (using Stra8-Cre deletion), resulted in no discernable phenotype, presumably because mTORC1 was already activated in these differentiating cells. Taken together, those results complement our findings here that mTORC1 is suppressed in undifferentiated spermatogonia, and that its activation is necessary for differentiation.

In summary, this study provides the first examination of the requirement for mTORC1 activation in spermatogonial
4. Materials and methods

4.1. Animal treatments and tissue collection

All animal procedures were performed in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee of East Carolina University (AUPs #A178a and #A193). Analyses were done using CD-1 mice (Charles River Laboratories) or Id4–GFP mice, which are on a C57Bl/6 background (Chan et al., 2014). Rapamycin was dissolved in DMSO and then diluted to a final concentration of 5 μg/μl in a solution of 5% polyethylene glycol 400 (Sigma-Aldrich) and 5% polysorbate 80 (Sigma-Aldrich). Rapamycin was fed daily using a 24-gauge feeding needle, in two regimens: (1) from P1–P3 and then euthanized at P4 or (2) from P1–P7 and then euthanized at P8. Using dosages similar to a previous study (Puighermanal et al., 2009), we fed CD-1 mice rapamycin at 0.25 mg/g body weight, and Id4–GFP mice received 10 μg/g. The administration of exogenous RA was done as previously described (Chappell et al., 2013). Briefly, neonatal mice received one subcutaneous injection of 100 μl all-trans RA (#R2625, Sigma-Aldrich) dissolved in 10 μl dimethyl sulfoxide (DMSO) or DMSO alone at P3, and were euthanized by decapitation 24 h later.

4.2. Polysome gradient analysis

Polysome gradients were performed as previously described (Chappell et al., 2013). Briefly, total testis lysates from at least 22 P4 vehicle- or rapamycin-treated mice were loaded onto 15 μl cutaneous injection of 100 administration of exogenous RA was done as previously described (Chappell et al., 2013). Briefly, total testis lysates from at least 22 P4 vehicle- or rapamycin-treated mice were loaded onto 15–45% linear sucrose gradient in polysome lysis buffer (100 mM KCl, 25 mM HEPES pH 7.4, 0.5% NP-40, and 100 μg/ml cycloheximide). Gradients were fractionated, and 14 successive fractions (9–14) were collected. RNA was isolated using TRIzol reagent based on manufacturer’s protocol from pooled heavy polysome fractions (9–14).

4.3. Quantitative RT-PCR

Quantitative RT-PCR (qRT-PCR) was performed in triplicate on total RNA isolated from pooled polysomal fractions and on RNA isolated from whole testis lysates from at least 3 different mice as before (Busada et al., 2015; Chappell et al., 2013). Briefly, generation of CDNA and amplification were performed in the same reaction tube using One-Step SYBR green and iScript polymerase (Bio-Rad) in an Applied Biosystems VIIa 7 Real-Time PCR System (Life Technologies). Primers were designed to span introns for Kit, Sohlh1, Sohlh2, Stra8, and B2m (Table 1). QRT-PCR was performed to measure the abundance of specific mRNAs within whole testis total RNA. Fold changes were calculated using the delta-delta Ct (ddCt) method using the reference gene B2m. Polysome occupancy of specific mRNAs was determined using qRT-PCR to amplify RNA isolated from pooled polysomal fractions. Relative mRNA levels were assessed using the dCt method from the lowest Ct in the group, and reported as a fold change.

4.4. Indirect Immunofluorescence (IIF)

IIF was performed as previously reported. Briefly, testes from at least 3 different mice were fixed in 4% PFA at 4°C. Testes were embedded in O.C.T., frozen, and cut into 5 μm sections. Sections were incubated with primary antibodies (see Table 2) for 1 h at room temperature. Following stringency washes, sections were incubated with either Alexa Fluor anti-goat or anti-rabbit secondary antibody (1:2000, Invitrogen) and phallloidin-635 or -594 (1:1000, Invitrogen). Coverslips were mounted with Vectastain containing DAPI (Vector Laboratories). Images were captured using a Fluoview FV1000 confocal laser-scanning microscope (Olympus America).

4.5. Cell quantitation

Immunostaining was performed on 5 μm frozen testis sections. Quantitation was carried out as previously described (Niedenberger et al., 2015), and immunostaining was performed for DX4 to mark all spermatagonia and spermatogonia in the neonatal testis. Germ cells within 21–30 testis cords were counted from 3 different animals. Cells were identified as positive for a marker if selected by the threshold tool in Image J (U.S. National Institutes of Health) using the default algorithm. Intensity thresholds were as follows: DX4=100–255, KIT=40–255, SOHLH1=90–255, SOHLH2=90–255. Testis sections from Id4–Gfp mice were immunostained with anti-DX4 antibodies. Photomicrographs were captured with an Axio Observer A1 microscope (Carl Zeiss Microscopy, LLC) equipped with an XL16C digital camera and Exponent version 1.3 software (Dage-MTI). Bright Id4–GFP+ cells were selected by Image J software with intensity thresholds set at 0–60. At least 400 DX4+ cells were selected from 4 testis sections, and the number of GFP-bright cells recorded. Testes were analyzed from at least 3 mice.

4.6. Statistics

Statistical analyses of the qRT-PCR results and cell counts were performed using Student’s t-test, and the level of significance was set at p ≤ 0.01.
Conflicts of interest

The authors do not have any conflicts to disclose.

Acknowledgments

The authors thank Joani Zary-Oswald for technical assistance, and Brian Hermann (University of Texas at San Antonio) for critically reading the manuscript. Antibodies against SOHLH1 and SOHLH2 were kindly provided by Alexandar Rajkovic (University of Pittsburgh, Magee-Womens Research Institute), and Id4-GFP transgenic mice were kindly provided by Jon Oatley (Washington State University). This work was supported by a Grant from the NIH/NICHHD (HD072552 to C.B.G.).

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.ydbio.2015.08.004.

References


Meng, X., Lindahl, M., Hyvonen, M.E., Parvinen, M., de Rooij, D.G., Hess, M.W.,
Masek, T., Valasek, L., Pospisek, M., 2011. Polysome analysis and RNA puri
Mark, M., Jacobs, H., Oulad-Abdelghani, M., Dennefeld, C., Feret, B., Vernet, N., Co-
Lopez-Carballo, G., Moreno, L., Masia, S., Perez, P., Barettino, D., 2002. Activation of
testis development but is not required for normal male reproduction. Sex. Dev.
Raatikainen-Ahokas, A., Sainio, K., Rauvala, H., Lakso, M., Pichel, J.G., Westphal,
Bryan, M.K., McLachlan, R.I., Stanton, P.G., 2011. Cannabinoid modulation of hippocampal long-term memory is
transcriptome: characterizing gene expression in the testes during the pro-
Snyder, E.M., Small, C., Griswold, M.D., 2010. Retinoic acid availability drives the
Shima, J.E., McLean, D.J., McCarrey, J.R., Griswold, M.D., 2008. Expression of stimulated by
Sahin, P., Sahin, Z., Gungor-Ordener, N.E., Donmez, B.O., Celik-Ozenci, C., 2014. In-
hibition of mammalian target of rapamycin signaling pathway decreases re-
transcriptome: characterizing gene expression in the testes during the pro-
Snyder, E.M., Small, C., Griswold, M.D., 2010. Retinoic acid availability drives the
Song, A., Labelia, S., Korneeva, N.L., Keiper, B.D., Aamodt, E.J., Zetka, M., Rhoads, R.E.,
Thoreen, C.C., Chantranupong, L., Keys, H.R., Wang, T., Gray, N.S., Sabatini, D.M.,
Wullischleger, S., Loeweth, R., Hall, M.N., 2006. TOR signaling in growth and meta-
Zaza, G., Tomes, P., Ria, P., Granata, S., Boschiervo, L., Lupo, A., 2013. Systemic and
Zhou, Q., Li, Y., Friel, P., Mitchell, D., Evanoff, R.M., Pouchnik, D., Banasik, B.,
McCarrey, J.R., Small, C., Griswold, M.D., 2008. Expression of stimulated by
etinoic acid gene 8 (Str8) and maturation of murine gonocytes and sperma-
Zhou, Q., Nie, R., Li, Y., Friel, P., Mitchell, D., Hess, R.A., Small, C., Griswold, M.D.,
Zuber, J., Anglicheau, D., Elie, C., Bererhi, L., Timso, M.O., Mamzer-Bruneel, M.F.,